{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:06:51Z","timestamp":1779199611353,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejmech.2026.118889","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:47:04Z","timestamp":1777528024000},"page":"118889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of preclinical candidate CG-0988, a novel severe acute respiratory syndrome coronavirus 2 3CL protease inhibitor bearing spirooxindole"],"prefix":"10.1016","volume":"314","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0782-0913","authenticated-orcid":false,"given":"Xiubo","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changliang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gong-Xin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118889_bib1","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib2","doi-asserted-by":"crossref","first-page":"101972","DOI":"10.1016\/j.jbc.2022.101972","article-title":"Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants","volume":"298","author":"Greasley","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib3","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332","volume":"13","author":"Zhao","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2026.118889_bib5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118889_bib6","first-page":"1","article-title":"Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB","volume":"88","author":"Imai","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118889_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109892","article-title":"Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome","volume":"37","author":"Pablos","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118889_bib8","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jacc.2022.08.800","article-title":"Cardiovascular drug interactions with nirmatrelvir\/ritonavir in patients with COVID-19","volume":"80","author":"Abraham","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2026.118889_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117846","article-title":"Discovery of macrocyclic covalent inhibitors for severe acute respiratory syndrome coronavirus 2 3CL protease","volume":"111","author":"Tang","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib11","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1021\/acs.jmedchem.3c02248","article-title":"Invention of MK-7845, a SARS-CoV-2 3CL protease inhibitor employing a novel difluorinated glutamine mimic","volume":"67","author":"Shurtleff","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib12","doi-asserted-by":"crossref","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","article-title":"A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19","volume":"67","author":"Allerton","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib13","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1021\/acs.jmedchem.4c02172","article-title":"Structure-based optimization of pyridone \u03b1-ketoamides as inhibitors of the SARS-CoV-2 main protease","volume":"68","author":"Akula H","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib14","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acs.jmedchem.0c01140","article-title":"Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities","volume":"65","author":"Cannalire","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.21783","article-title":"What coronavirus 3C\u2010like protease tells us: from structure, substrate selectivity, to inhibitor design","volume":"41","author":"Xiong","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118889_bib16","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1039\/D1MD00247C","article-title":"Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Bai","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib17","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118889_bib18","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1021\/acs.jmedchem.4c02561","article-title":"Discovery of nirmatrelvir (PF-07321332): a potent, orally active inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease","volume":"68","author":"Tuttle","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib19","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib20","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1021\/acs.jafc.6b02683","article-title":"Design, Synthesis, and biological activities of spirooxindoles containing acylhydrazone fragment derivatives based on the biosynthesis of alkaloids derived from tryptophan","volume":"64","author":"Chen","year":"2016","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib21","article-title":"Novel spiropyrrolidine derived antiviral agents","author":"Shen","year":"2023","journal-title":"WO 2023\/009187Al"},{"key":"10.1016\/j.ejmech.2026.118889_bib22","article-title":"Discovery of peptidomimetic spiropyrrolidine derivatives as novel 3CLpro inhibitors against SARS-CoV -2","volume":"281","author":"Guama","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib23","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1016\/j.bmcl.2009.06.091","article-title":"Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center","volume":"19","author":"Nizi","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118889_bib24","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1021\/jm100087s","article-title":"Intramolecular hydrogen bonding in medicinal chemistry","volume":"53","author":"Kuhn","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib25","doi-asserted-by":"crossref","first-page":"13639","DOI":"10.1021\/acs.jmedchem.4c00190","article-title":"Identification and characterization of a blood\u2212brain barrier penetrant inositol hexakisphosphate kinase (IP6K) inhibitor","volume":"67","author":"Heitmann","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118889_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/molecules22030423","article-title":"Intramolecular hydrogen bonding involving organic fluorine: NMR investigations corroborated by DFT-based theoretical calculations","volume":"22","author":"Mishra","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118889_bib27","first-page":"306","article-title":"Organic fluorine as a hydrogen-bond acceptor: recent examples and applications","volume":"47","author":"Champagne","year":"2015","journal-title":"Synthesis"},{"key":"10.1016\/j.ejmech.2026.118889_bib28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1246\/cl.1993.691","article-title":"Trans to cis one-way photoisomerization of an olefin substituted with and indole and a pyridine ring. Effect of intramolecular hydrogen bond","author":"Arai","year":"1993","journal-title":"Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118889_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127742","article-title":"Discovery of novel HIV-1 integrase-LEDGF\/p75 allosteric inhibitors based on a pyridine scaffold forming an intramolecular hydrogen bond","volume":"33","author":"Sugiyama","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118889_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2022.107229","article-title":"Determination of five positive control drugs in hERG external solution (Buffer) by LC-MS\/MS to support in Vitro hERG assay as recommended by ICH S7B","volume":"118","author":"King","year":"2022","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejmech.2026.118889_bib31","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118889_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/cjoc.20020200116","article-title":"Synthesis of a new class of chiral \u03b2-mercaptoalcohols from amino acids","volume":"20","author":"Ge","year":"2002","journal-title":"Chin. J. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600334X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600334X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:10:10Z","timestamp":1779196210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342600334X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S022352342600334X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118889","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of preclinical candidate CG-0988, a novel severe acute respiratory syndrome coronavirus 2 3CL protease inhibitor bearing spirooxindole","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118889"}}